Fulcrum stock slumps after muscle disorder drug fails in late-stage study - Health News - News 247

Jump to content

Existing user? Sign In
Sign In

Remember me Not recommended on shared computers

Forgot your password?
Sign Up

ADS

ADS

ADS

ADS

Fulcrum stock slumps after muscle disorder drug fails in late-stage study
(0 reviews)
By Author

September 13
Share
https://news247.center/news/health-news/fulcrum-stock-slumps-after-muscle-disorder-drug-fails-in-late-stage-study-r34/

Followers 0
FSHD is a genetic disorder that causes muscle weakness and wasting in the face, shoulder blades and upper arms. The estimated prevalence of the disease is about 4 cases per 100,000 individuals, according to the Muscle Dystrophy Association.
Source Link
Share
https://news247.center/news/health-news/fulcrum-stock-slumps-after-muscle-disorder-drug-fails-in-late-stage-study-r34/
Followers 0
Go to articles

User Feedback
- 0 Reviews
- 0 Comments
Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Your email address Required

This will not be shown to other users.

Your rating Required

1 2 3 4 5

Your review Required

Add a review...

× Pasted as rich text.   Paste as plain text instead

Only 75 emoji are allowed.

× Your link has been automatically embedded.   Display as a link instead

× Your previous content has been restored.   Clear editor

× You cannot paste images directly. Upload or insert images from URL.

Insert image from URL

×

Desktop

Tablet

Phone
ADS

ADS

×

News
- Back
- News
- Arts & Lifestyle
- Finance
- Gaming
- Health
- History
- Politics
- Science
- Sports
- Technology
- World
Forums

×

Create New...

Important Information

Cookie Consent & Terms We use cookies to enhance your experience on our site. By continuing to browse our website, you agree to our use of cookies as outlined in our We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.. Please review our Terms of Use, Privacy Policy, and Guidelines for more information.